Identification

Name
Phenprocoumon
Accession Number
DB00946  (APRD00228)
Type
Small Molecule
Groups
Approved, Investigational
Description

Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]

Structure
Thumb
Synonyms
  • 3-(1-Phenylpropyl)-4-hydroxycoumarin
  • 3-(1'-Phenyl-propyl)-4-oxycoumarin
  • 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin
  • 3-(alpha-Phenylpropyl)-4-hydroxycoumarin
  • 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one
  • 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
  • Fenprocumon
  • Fenprocumone
  • Phenprocoumarol
  • Phenprocoumarole
  • Phenprocoumone
  • Phenprocoumonum
  • Phenprocumone
International/Other Brands
Falithrom / Marcoumar / Marcumar
Categories
UNII
Q08SIO485D
CAS number
435-97-2
Weight
Average: 280.3178
Monoisotopic: 280.109944378
Chemical Formula
C18H16O3
InChI Key
DQDAYGNAKTZFIW-UHFFFAOYSA-N
InChI
InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
IUPAC Name
4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
SMILES
CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2

Pharmacology

Indication

Used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).

Pharmacodynamics

Phenprocoumon, a coumarin anticoagulant, thins the blood by antagonizing vitamin K which is required for the production of clotting factors in the liver. Anticoagulants such as phenprocoumon have no direct effect on an established thrombus, nor do they reverse ischemic tissue damage (damage caused by an inadequate blood supply to an organ or part of the body). However, once a thrombus has occurred, the goal of anticoagulant treatment is to prevent further extension of the formed clot and prevent secondary thromboembolic complications which may result in serious and possibly fatal sequelae.

Mechanism of action

Phenprocoumon inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.

TargetActionsOrganism
AVitamin K epoxide reductase complex subunit 1
inhibitor
Human
Absorption

Bioavailability is close to 100%

Volume of distribution
Not Available
Protein binding

99%

Metabolism

Phenprocoumon is stereoselectively metabolized by hepatic microsomal enzymes (cytochrome P-450) to inactive hydroxylated metabolites (predominant route) and by reductases to reduced metabolites. Cytochrome P450 2C9 is the principal form of human liver P-450 responsible for metabolism.

Route of elimination
Not Available
Half life

5-6 days

Clearance
Not Available
Toxicity

50=500 mg/kg. Symptoms of overdose includes suspected or overt abnormal bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Phenprocoumon Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*2(T;T) / (C;T)T AlleleADR Directly StudiedThe presence of this polymorphism in CYP2C9 is associated with reduction in phenprocoumon metabolism.Details
Cytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C AlleleADR Directly StudiedThe presence of this polymorphism in CYP2C9 is associated with reduction in phenprocoumon metabolism.Details
Vitamin K epoxide reductase complex subunit 1---(A;A) / (A;G)G > AADR Directly StudiedThe presence of this polymorphism in VKORC1 is associated with reduction in phenprocoumon metabolism.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*15Not Available485C>AADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*3Not Available1075A>CADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*8Not Available449G>AADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*13Not Available269T>CADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*14Not Available374G>AADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*16Not Available895A>GADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all ADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*26Not Available389C>GADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*28Not Available641A>TADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details
Cytochrome P450 2C9CYP2C9*33Not Available395G>AADR InferredAssociated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Phenprocoumon.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Phenprocoumon.Approved
AbirateroneThe serum concentration of Phenprocoumon can be increased when it is combined with Abiraterone.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Phenprocoumon is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPhenprocoumon may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenAcetaminophen may increase the anticoagulant activities of Phenprocoumon.Approved
AcetohexamideAcetohexamide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Phenprocoumon can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Phenprocoumon.Approved
AlaproclateAlaproclate may increase the anticoagulant activities of Phenprocoumon.Experimental
AlclofenacAlclofenac may increase the anticoagulant activities of Phenprocoumon.Approved, Withdrawn
AllopurinolAllopurinol may increase the anticoagulant activities of Phenprocoumon.Approved
AllylestrenolThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Phenprocoumon.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Phenprocoumon.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Phenprocoumon.Approved
AltrenogestThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Altrenogest.Vet Approved
Aluminium clofibrateAluminium clofibrate may increase the anticoagulant activities of Phenprocoumon.Experimental
AmdinocillinAmdinocillin may increase the anticoagulant activities of Phenprocoumon.Investigational, Withdrawn
AmineptineAmineptine may increase the anticoagulant activities of Phenprocoumon.Illicit, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Phenprocoumon.Approved
AmiodaroneThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the anticoagulant activities of Phenprocoumon.Approved
AmitriptylinoxideAmitriptylinoxide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
AmobarbitalThe metabolism of Phenprocoumon can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the anticoagulant activities of Phenprocoumon.Approved
AmoxicillinAmoxicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
AmpicillinAmpicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Phenprocoumon.Approved
AncrodPhenprocoumon may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Phenprocoumon.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Phenprocoumon.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Phenprocoumon.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Antithrombin III humanPhenprocoumon may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineAntrafenine may increase the anticoagulant activities of Phenprocoumon.Approved
ApalutamideThe serum concentration of Phenprocoumon can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanApixaban may increase the anticoagulant activities of Phenprocoumon.Approved
ApocyninApocynin may increase the anticoagulant activities of Phenprocoumon.Investigational
ApremilastApremilast may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
AprepitantThe serum concentration of Phenprocoumon can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
AspoxicillinAspoxicillin may increase the anticoagulant activities of Phenprocoumon.Experimental
AstaxanthinAstaxanthin may increase the anticoagulant activities of Phenprocoumon.Investigational
AtazanavirThe metabolism of Phenprocoumon can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Phenprocoumon can be decreased when combined with Atomoxetine.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Phenprocoumon.Withdrawn
AzathioprineAzathioprine may decrease the anticoagulant activities of Phenprocoumon.Approved
AzelastineAzelastine may increase the anticoagulant activities of Phenprocoumon.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Azficel-T.Approved, Investigational
AzidocillinAzidocillin may increase the anticoagulant activities of Phenprocoumon.Approved
AzithromycinThe serum concentration of Phenprocoumon can be increased when it is combined with Azithromycin.Approved
AzlocillinAzlocillin may increase the anticoagulant activities of Phenprocoumon.Approved
BacampicillinBacampicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
BarbexacloneThe metabolism of Phenprocoumon can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Phenprocoumon can be increased when combined with Barbital.Illicit
BatroxobinBatroxobin may increase the anticoagulant activities of Phenprocoumon.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Phenprocoumon.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Phenprocoumon.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Phenprocoumon.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Phenprocoumon.Approved
BenzylpenicillinBenzylpenicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
Benzylpenicilloyl PolylysineBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Phenprocoumon.Approved
BeraprostBeraprost may increase the anticoagulant activities of Phenprocoumon.Investigational
BevoniumBevonium may increase the anticoagulant activities of Phenprocoumon.Experimental
BezafibrateBezafibrate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
BicalutamideThe serum concentration of Phenprocoumon can be increased when it is combined with Bicalutamide.Approved
BivalirudinBivalirudin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
BoceprevirThe metabolism of Phenprocoumon can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Phenprocoumon can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Phenprocoumon can be increased when combined with Bosentan.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Phenprocoumon.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Phenprocoumon.Approved
BucillamineBucillamine may increase the anticoagulant activities of Phenprocoumon.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Phenprocoumon.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Phenprocoumon.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Phenprocoumon.Experimental
ButriptylineButriptyline may increase the anticoagulant activities of Phenprocoumon.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Phenprocoumon.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Phenprocoumon.Approved
CapecitabineThe serum concentration of Phenprocoumon can be increased when it is combined with Capecitabine.Approved, Investigational
CaplacizumabCaplacizumab may increase the anticoagulant activities of Phenprocoumon.Investigational
CapsaicinCapsaicin may increase the anticoagulant activities of Phenprocoumon.Approved
CarbamazepineThe serum concentration of Phenprocoumon can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Phenprocoumon.Experimental, Investigational
CarbenicillinCarbenicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Carbenicillin indanylCarbenicillin indanyl may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CarbimazoleCarbimazole may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
CarbomycinThe serum concentration of Phenprocoumon can be increased when it is combined with Carbomycin.Vet Approved
CarbutamideCarbutamide may increase the anticoagulant activities of Phenprocoumon.Experimental
CarfecillinCarfecillin may increase the anticoagulant activities of Phenprocoumon.Experimental
CarprofenCarprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Phenprocoumon.Experimental
CefacetrileCefacetrile may increase the anticoagulant activities of Phenprocoumon.Approved
CefaclorCefaclor may increase the anticoagulant activities of Phenprocoumon.Approved
CefadroxilCefadroxil may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved, Withdrawn
CefalotinCefalotin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
CefamandoleCefamandole may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CefapirinCefapirin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
CefatrizineCefatrizine may increase the anticoagulant activities of Phenprocoumon.Experimental
CefazedoneCefazedone may increase the anticoagulant activities of Phenprocoumon.Experimental
CefazolinCefazolin may increase the anticoagulant activities of Phenprocoumon.Approved
CefbuperazoneCefbuperazone may increase the anticoagulant activities of Phenprocoumon.Experimental
CefcapeneCefcapene may increase the anticoagulant activities of Phenprocoumon.Experimental
CefdinirCefdinir may increase the anticoagulant activities of Phenprocoumon.Approved
CefditorenCefditoren may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CefepimeCefepime may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CefetametCefetamet may increase the anticoagulant activities of Phenprocoumon.Experimental
CefiximeCefixime may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CefmenoximeCefmenoxime may increase the anticoagulant activities of Phenprocoumon.Approved
CefmetazoleCefmetazole may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CefminoxCefminox may increase the anticoagulant activities of Phenprocoumon.Approved
CefodizimeCefodizime may increase the anticoagulant activities of Phenprocoumon.Experimental
CefonicidCefonicid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CefoperazoneCefoperazone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CeforanideCeforanide may increase the anticoagulant activities of Phenprocoumon.Approved
CefotaximeCefotaxime may increase the anticoagulant activities of Phenprocoumon.Approved
CefotetanCefotetan may increase the anticoagulant activities of Phenprocoumon.Approved
CefotiamCefotiam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CefoxitinCefoxitin may increase the anticoagulant activities of Phenprocoumon.Approved
CefozopranCefozopran may increase the anticoagulant activities of Phenprocoumon.Experimental
CefpiromeCefpirome may increase the anticoagulant activities of Phenprocoumon.Approved
CefpodoximeCefpodoxime may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
CefprozilCefprozil may increase the anticoagulant activities of Phenprocoumon.Approved
CefradineCefradine may increase the anticoagulant activities of Phenprocoumon.Approved
CefroxadineCefroxadine may increase the anticoagulant activities of Phenprocoumon.Withdrawn
CefsulodinCefsulodin may increase the anticoagulant activities of Phenprocoumon.Experimental
Ceftaroline fosamilCeftaroline fosamil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CeftazidimeCeftazidime may increase the anticoagulant activities of Phenprocoumon.Approved
CeftezoleCeftezole may increase the anticoagulant activities of Phenprocoumon.Experimental
CeftibutenCeftibuten may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CeftizoximeCeftizoxime may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CeftobiproleCeftobiprole may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CeftriaxoneCeftriaxone may increase the anticoagulant activities of Phenprocoumon.Approved
CefuroximeCefuroxime may increase the anticoagulant activities of Phenprocoumon.Approved
CelecoxibCelecoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CephalexinCephalexin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
CephaloglycinCephaloglycin may increase the anticoagulant activities of Phenprocoumon.Approved
CephaloridineCephaloridine may increase the anticoagulant activities of Phenprocoumon.Approved, Withdrawn
CeritinibThe serum concentration of Phenprocoumon can be increased when it is combined with Ceritinib.Approved
CertoparinPhenprocoumon may increase the anticoagulant activities of Certoparin.Approved, Investigational
Chloral hydrateThe serum concentration of Phenprocoumon can be increased when it is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolChloramphenicol may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
ChlormadinoneChlormadinone may decrease the anticoagulant activities of Phenprocoumon.Experimental
ChloroquineChloroquine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Phenprocoumon.Investigational, Withdrawn
ChlorphenesinChlorphenesin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved, Withdrawn
ChlorpropamideChlorpropamide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ChlortetracyclineChlortetracycline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
CholecalciferolThe metabolism of Phenprocoumon can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Phenprocoumon.Approved
CilostazolCilostazol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CimetidineCimetidine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CimicoxibCimicoxib may increase the anticoagulant activities of Phenprocoumon.Investigational
CinoxacinCinoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
CiprofibrateCiprofibrate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CisplatinCisplatin may increase the anticoagulant activities of Phenprocoumon.Approved
CitalopramCitalopram may increase the anticoagulant activities of Phenprocoumon.Approved
Citric AcidPhenprocoumon may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Phenprocoumon can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Phenprocoumon can be decreased when combined with Clemastine.Approved, Investigational
Clodronic AcidClodronic Acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
ClofibrateClofibrate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ClofibrideClofibride may increase the anticoagulant activities of Phenprocoumon.Experimental
ClomipramineClomipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Phenprocoumon.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Phenprocoumon.Approved
CloricromenCloricromen may increase the anticoagulant activities of Phenprocoumon.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Phenprocoumon.Experimental
ClotrimazoleThe metabolism of Phenprocoumon can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxacillinCloxacillin may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
CobicistatThe metabolism of Phenprocoumon can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Phenprocoumon.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Phenprocoumon.Approved
CranberryCranberry may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
CrisaboroleThe metabolism of Phenprocoumon can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Phenprocoumon can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Phenprocoumon can be decreased when combined with Curcumin.Approved, Investigational
CyclacillinCyclacillin may increase the anticoagulant activities of Phenprocoumon.Approved
CyclosporineThe metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateCyproterone acetate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Phenprocoumon.Approved
DabrafenibThe serum concentration of Phenprocoumon can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinDaidzein may decrease the anticoagulant activities of Phenprocoumon.Experimental
DalteparinPhenprocoumon may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPhenprocoumon may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolDanazol may increase the anticoagulant activities of Phenprocoumon.Approved
DapoxetineDapoxetine may increase the anticoagulant activities of Phenprocoumon.Investigational
DarexabanPhenprocoumon may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Phenprocoumon can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
DeferasiroxThe serum concentration of Phenprocoumon can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
DelavirdineThe metabolism of Phenprocoumon can be decreased when combined with Delavirdine.Approved
DemeclocyclineDemeclocycline may increase the anticoagulant activities of Phenprocoumon.Approved
DemegestoneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Demegestone.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Phenprocoumon.Investigational
DesipramineDesipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
DesirudinPhenprocoumon may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Phenprocoumon.Investigational
DesogestrelDesogestrel may decrease the anticoagulant activities of Phenprocoumon.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenprocoumon.Approved, Investigational
DexibuprofenDexibuprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
DexketoprofenDexketoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
DexmethylphenidateThe serum concentration of Phenprocoumon can be increased when it is combined with Dexmethylphenidate.Approved, Investigational
DextranPhenprocoumon may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibenzepinDibenzepin may increase the anticoagulant activities of Phenprocoumon.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
DicloxacillinDicloxacillin may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Phenprocoumon.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
DienogestDienogest may decrease the anticoagulant activities of Phenprocoumon.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Phenprocoumon.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
DihydroergotamineThe metabolism of Phenprocoumon can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Phenprocoumon can be decreased when combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may increase the anticoagulant activities of Phenprocoumon.Approved, Withdrawn
DiphenadioneDiphenadione may increase the anticoagulant activities of Phenprocoumon.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Phenprocoumon.Approved
DisulfiramThe serum concentration of Phenprocoumon can be increased when it is combined with Disulfiram.Approved
DitazoleDitazole may increase the anticoagulant activities of Phenprocoumon.Approved, Withdrawn
DosulepinThe metabolism of Phenprocoumon can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
DoxycyclineThe metabolism of Phenprocoumon can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Phenprocoumon can be increased when it is combined with Dronedarone.Approved
DrospirenoneDrospirenone may decrease the anticoagulant activities of Phenprocoumon.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Phenprocoumon.Withdrawn
DuloxetineDuloxetine may increase the anticoagulant activities of Phenprocoumon.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Phenprocoumon.Investigational
DydrogesteroneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Phenprocoumon.Investigational
EconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Econazole.Approved
Edetic AcidPhenprocoumon may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Phenprocoumon.Approved
EfavirenzThe serum concentration of Phenprocoumon can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinEnoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
EnoxaparinPhenprocoumon may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Phenprocoumon can be decreased when it is combined with Enzalutamide.Approved
EpicillinEpicillin may increase the anticoagulant activities of Phenprocoumon.Experimental
EpimestrolEpimestrol may decrease the anticoagulant activities of Phenprocoumon.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Phenprocoumon.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Phenprocoumon.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Phenprocoumon.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Phenprocoumon.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Phenprocoumon.Investigational
ErythromycinThe serum concentration of Phenprocoumon can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
EsomeprazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Phenprocoumon.Approved
EstroneEstrone may decrease the anticoagulant activities of Phenprocoumon.Approved
Etacrynic acidThe serum concentration of Phenprocoumon can be increased when it is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
EthanolThe serum concentration of Phenprocoumon can be decreased when it is combined with Ethanol.Approved
EthenzamideEthenzamide may increase the anticoagulant activities of Phenprocoumon.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Phenprocoumon.Approved
EthotoinEthotoin may increase the anticoagulant activities of Phenprocoumon.Approved
Ethyl biscoumacetatePhenprocoumon may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Ethynodiol.Experimental
Ethynodiol diacetateEthynodiol diacetate may decrease the anticoagulant activities of Phenprocoumon.Approved
EtodolacEtodolac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
EtofibrateEtofibrate may increase the anticoagulant activities of Phenprocoumon.Approved
EtonogestrelEtonogestrel may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
EtoperidoneEtoperidone may increase the anticoagulant activities of Phenprocoumon.Withdrawn
EtoposideEtoposide may increase the anticoagulant activities of Phenprocoumon.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
EtravirineThe metabolism of Phenprocoumon can be decreased when combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Phenprocoumon.Investigational, Nutraceutical
ExenatideExenatide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Phenprocoumon.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Phenprocoumon.Experimental
FelodipineThe metabolism of Phenprocoumon can be decreased when combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Phenprocoumon.Approved
FenofibrateFenofibrate may increase the anticoagulant activities of Phenprocoumon.Approved
Fenofibric acidFenofibric acid may increase the anticoagulant activities of Phenprocoumon.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Phenprocoumon.Approved
FentiazacFentiazac may increase the anticoagulant activities of Phenprocoumon.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Phenprocoumon.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Phenprocoumon.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Phenprocoumon.Investigational
Fish oilFish oil may increase the anticoagulant activities of Phenprocoumon.Approved, Nutraceutical
FleroxacinFleroxacin may increase the anticoagulant activities of Phenprocoumon.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Phenprocoumon.Approved, Withdrawn
FloxuridineThe metabolism of Phenprocoumon can be decreased when combined with Floxuridine.Approved
FlucloxacillinFlucloxacillin may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
FluconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Fluconazole.Approved, Investigational
FluindionePhenprocoumon may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineFlumequine may increase the anticoagulant activities of Phenprocoumon.Withdrawn
FlunixinFlunixin may increase the anticoagulant activities of Phenprocoumon.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Phenprocoumon.Experimental
FluorouracilThe serum concentration of Phenprocoumon can be increased when it is combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the anticoagulant activities of Phenprocoumon.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
FluvastatinThe metabolism of Phenprocoumon can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Phenprocoumon can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxFondaparinux sodium may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
FosamprenavirThe metabolism of Phenprocoumon can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Phenprocoumon can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Fusidic AcidThe serum concentration of Phenprocoumon can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexatePhenprocoumon may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinGarenoxacin may increase the anticoagulant activities of Phenprocoumon.Investigational
GatifloxacinGatifloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
GefitinibGefitinib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
GemfibrozilGemfibrozil may increase the anticoagulant activities of Phenprocoumon.Approved
GemifloxacinGemifloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
GenisteinGenistein may decrease the anticoagulant activities of Phenprocoumon.Investigational
GestodeneGestodene may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
GestonoroneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Gestrinone.Approved
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Phenprocoumon.Approved, Investigational, Nutraceutical
GinsengGinseng may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Nutraceutical
GlibornurideGlibornuride may increase the anticoagulant activities of Phenprocoumon.Investigational, Withdrawn
GliclazideGliclazide may increase the anticoagulant activities of Phenprocoumon.Approved
GlimepirideGlimepiride may increase the anticoagulant activities of Phenprocoumon.Approved
GlipizideGlipizide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
GliquidoneGliquidone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
GlisoxepideGlisoxepide may increase the anticoagulant activities of Phenprocoumon.Investigational
GLPG-0492GLPG-0492 may increase the anticoagulant activities of Phenprocoumon.Investigational
Glucagon recombinantGlucagon recombinant may increase the anticoagulant activities of Phenprocoumon.Approved
GlutethimideThe metabolism of Phenprocoumon can be increased when combined with Glutethimide.Approved, Illicit
GlyburideGlyburide may increase the anticoagulant activities of Phenprocoumon.Approved
GrepafloxacinGrepafloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
GriseofulvinThe serum concentration of Phenprocoumon can be decreased when it is combined with Griseofulvin.Approved, Investigational, Vet Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Phenprocoumon.Experimental
HeminHemin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Phenprocoumon.Experimental
HeparinPhenprocoumon may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Phenprocoumon.Withdrawn
HexobarbitalThe metabolism of Phenprocoumon can be increased when combined with Hexobarbital.Approved
HigenamineHigenamine may increase the anticoagulant activities of Phenprocoumon.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Phenprocoumon.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Phenprocoumon.Approved
IbudilastIbudilast may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Phenprocoumon.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Phenprocoumon.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
IcosapentIcosapent may increase the anticoagulant activities of Phenprocoumon.Approved, Nutraceutical
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Nutraceutical
IdelalisibThe metabolism of Phenprocoumon can be decreased when combined with Idelalisib.Approved
IdraparinuxPhenprocoumon may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Phenprocoumon.Investigational
IfosfamideIfosfamide may increase the anticoagulant activities of Phenprocoumon.Approved
IloprostIloprost may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ImatinibThe metabolism of Phenprocoumon can be decreased when combined with Imatinib.Approved
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Phenprocoumon.Experimental
ImipramineImipramine may increase the anticoagulant activities of Phenprocoumon.Approved
IndalpineIndalpine may increase the anticoagulant activities of Phenprocoumon.Investigational, Withdrawn
IndinavirThe metabolism of Phenprocoumon can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Phenprocoumon.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Phenprocoumon.Withdrawn
IprindoleIprindole may increase the anticoagulant activities of Phenprocoumon.Experimental
IrbesartanThe metabolism of Phenprocoumon can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Phenprocoumon can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Phenprocoumon.Withdrawn
IsradipineThe metabolism of Phenprocoumon can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Phenprocoumon can be increased when it is combined with Ivacaftor.Approved
IvermectinIvermectin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
JosamycinThe serum concentration of Phenprocoumon can be increased when it is combined with Josamycin.Approved, Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Phenprocoumon.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Phenprocoumon.Investigational
KetoconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Phenprocoumon.Approved
KitasamycinThe serum concentration of Phenprocoumon can be increased when it is combined with Kitasamycin.Experimental
L-CarnitineL-Carnitine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
LansoprazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe metabolism of Phenprocoumon can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
LepirudinPhenprocoumon may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPhenprocoumon may increase the anticoagulant activities of Letaxaban.Investigational
LevofloxacinLevofloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Phenprocoumon.Approved, Investigational
LevonorgestrelLevonorgestrel may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
LevothyroxineLevothyroxine may increase the anticoagulant activities of Phenprocoumon.Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Phenprocoumon.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Phenprocoumon.Experimental
LiothyronineLiothyronine may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
LiotrixLiotrix may increase the anticoagulant activities of Phenprocoumon.Approved
LisofyllineLisofylline may increase the anticoagulant activities of Phenprocoumon.Investigational
LixisenatideLixisenatide can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LobeglitazoneThe metabolism of Phenprocoumon can be decreased when combined with Lobeglitazone.Approved, Investigational
LofepramineLofepramine may increase the anticoagulant activities of Phenprocoumon.Experimental
LomefloxacinLomefloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
LonazolacLonazolac may increase the anticoagulant activities of Phenprocoumon.Experimental
LopinavirThe metabolism of Phenprocoumon can be decreased when combined with Lopinavir.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
LorpiprazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Phenprocoumon can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Phenprocoumon can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
LuliconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Phenprocoumon can be increased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
LynestrenolLynestrenol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Phenprocoumon.Approved
ManidipineThe metabolism of Phenprocoumon can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolMasoprocol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateMedroxyprogesterone acetate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Phenprocoumon.Approved
Megestrol acetateThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranPhenprocoumon may increase the anticoagulant activities of Melagatran.Experimental
MelitracenMelitracen may increase the anticoagulant activities of Phenprocoumon.Experimental, Investigational
MeloxicamMeloxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
MercaptopurineMercaptopurine may decrease the anticoagulant activities of Phenprocoumon.Approved
MesalazineMesalazine may increase the anticoagulant activities of Phenprocoumon.Approved
MesteroloneMesterolone may increase the anticoagulant activities of Phenprocoumon.Experimental
MestranolMestranol may decrease the anticoagulant activities of Phenprocoumon.Approved
MetahexamideMetahexamide may increase the anticoagulant activities of Phenprocoumon.Experimental
MetamizoleMetamizole may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
MetampicillinMetampicillin may increase the anticoagulant activities of Phenprocoumon.Experimental
MethallenestrilMethallenestril may decrease the anticoagulant activities of Phenprocoumon.Experimental
MethimazoleMethimazole may decrease the anticoagulant activities of Phenprocoumon.Approved
MethohexitalThe metabolism of Phenprocoumon can be increased when combined with Methohexital.Approved
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Methylestrenolone.Experimental
MethylphenidateThe serum concentration of Phenprocoumon can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Phenprocoumon can be increased when combined with Methylphenobarbital.Approved
MethyltestosteroneMethyltestosterone may increase the anticoagulant activities of Phenprocoumon.Approved
MethylthiouracilMethylthiouracil may decrease the anticoagulant activities of Phenprocoumon.Experimental
MeticillinMeticillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
MetronidazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Metronidazole.Approved
MezlocillinMezlocillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
MiconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Phenprocoumon can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Phenprocoumon can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Phenprocoumon.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Phenprocoumon.Approved
MinocyclineMinocycline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
MitotaneThe serum concentration of Phenprocoumon can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may increase the anticoagulant activities of Phenprocoumon.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Phenprocoumon.Experimental
MorniflumateMorniflumate may increase the anticoagulant activities of Phenprocoumon.Approved
MoxestrolMoxestrol may decrease the anticoagulant activities of Phenprocoumon.Experimental
MoxifloxacinMoxifloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Phenprocoumon.Approved
NabiloneThe metabolism of Phenprocoumon can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may increase the anticoagulant activities of Phenprocoumon.Approved
NadroparinPhenprocoumon may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
NafcillinNafcillin may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Phenprocoumon.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Phenprocoumon.Investigational
Nalidixic AcidNalidixic Acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
NandroloneNandrolone may increase the anticoagulant activities of Phenprocoumon.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the anticoagulant activities of Phenprocoumon.Approved, Illicit
NaproxenNaproxen may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
NefazodoneThe metabolism of Phenprocoumon can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Phenprocoumon can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the anticoagulant activities of Phenprocoumon.Investigational
NeomycinNeomycin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
NetupitantThe serum concentration of Phenprocoumon can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Phenprocoumon can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Phenprocoumon can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Phenprocoumon.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Phenprocoumon.Approved
NilotinibThe metabolism of Phenprocoumon can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Phenprocoumon.Investigational
NomegestrolThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Nomegestrol.Approved
Nomegestrol acetateNomegestrol acetate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
NorelgestrominNorelgestromin may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Norethisterone.Approved
NorethynodrelNorethynodrel may decrease the anticoagulant activities of Phenprocoumon.Approved
NorfloxacinNorfloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
NorgestimateNorgestimate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
NorgestrelNorgestrel may decrease the anticoagulant activities of Phenprocoumon.Approved
NorgestrienoneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineNortriptyline may increase the anticoagulant activities of Phenprocoumon.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Obinutuzumab.Approved, Investigational
OfloxacinOfloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
OlaparibThe metabolism of Phenprocoumon can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Phenprocoumon can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Phenprocoumon.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Phenprocoumon.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Phenprocoumon is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Phenprocoumon.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OmeprazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolOpipramol may increase the anticoagulant activities of Phenprocoumon.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Phenprocoumon.Vet Approved
OritavancinThe serum concentration of Phenprocoumon can be increased when it is combined with Oritavancin.Approved, Investigational
OsimertinibThe serum concentration of Phenprocoumon can be increased when it is combined with Osimertinib.Approved
OtamixabanPhenprocoumon may increase the anticoagulant activities of Otamixaban.Investigational
OxacillinOxacillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
OxandroloneOxandrolone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Phenprocoumon.Approved
Oxolinic acidOxolinic acid may increase the anticoagulant activities of Phenprocoumon.Experimental
OxymetholoneOxymetholone may increase the anticoagulant activities of Phenprocoumon.Approved, Illicit
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Phenprocoumon.Approved, Withdrawn
OxytetracyclineOxytetracycline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
OzagrelOzagrel may increase the anticoagulant activities of Phenprocoumon.Investigational
PalbociclibThe serum concentration of Phenprocoumon can be increased when it is combined with Palbociclib.Approved, Investigational
PalmidrolPalmidrol may increase the anticoagulant activities of Phenprocoumon.Experimental, Nutraceutical
ParecoxibParecoxib may increase the anticoagulant activities of Phenprocoumon.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ParoxetineParoxetine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PazufloxacinPazufloxacin may increase the anticoagulant activities of Phenprocoumon.Investigational
PefloxacinPefloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PenamecillinPenamecillin may increase the anticoagulant activities of Phenprocoumon.Experimental
Pentaerythritol TetranitratePhenprocoumon may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Phenprocoumon can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Phenprocoumon.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenobarbitalThe metabolism of Phenprocoumon can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxymethylpenicillinPhenoxymethylpenicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
PhenytoinPhenytoin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
PhylloquinonePhylloquinone may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamidePicotamide may increase the anticoagulant activities of Phenprocoumon.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PioglitazoneThe metabolism of Phenprocoumon can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidPipemidic acid may increase the anticoagulant activities of Phenprocoumon.Experimental
PiperacillinPiperacillin may increase the anticoagulant activities of Phenprocoumon.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Piromidic acidPiromidic acid may increase the anticoagulant activities of Phenprocoumon.Experimental
PiroxicamPiroxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Phenprocoumon.Experimental
PitolisantThe serum concentration of Phenprocoumon can be decreased when it is combined with Pitolisant.Approved, Investigational
PivampicillinPivampicillin may increase the anticoagulant activities of Phenprocoumon.Approved
PivmecillinamPivmecillinam may increase the anticoagulant activities of Phenprocoumon.Approved
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Phenprocoumon.Approved
PomalidomidePomalidomide may increase the anticoagulant activities of Phenprocoumon.Approved
PosaconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitratePhenprocoumon may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
Potassium IodidePotassium Iodide may decrease the anticoagulant activities of Phenprocoumon.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Phenprocoumon.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Phenprocoumon.Approved
PrimidoneThe metabolism of Phenprocoumon can be increased when combined with Primidone.Approved, Vet Approved
Procaine benzylpenicillinProcaine benzylpenicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Phenprocoumon.Experimental
PromegestoneThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Phenprocoumon.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PropafenoneThe serum concentration of Phenprocoumon can be increased when it is combined with Propafenone.Approved
PropicillinPropicillin may increase the anticoagulant activities of Phenprocoumon.Experimental
PropylthiouracilPropylthiouracil may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Phenprocoumon.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Phenprocoumon.Experimental
Protein CPhenprocoumon may increase the anticoagulant activities of Protein C.Approved
Protein S humanPhenprocoumon may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePhenprocoumon may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineProtriptyline may increase the anticoagulant activities of Phenprocoumon.Approved
PrulifloxacinPrulifloxacin may increase the anticoagulant activities of Phenprocoumon.Investigational
PTC299PTC299 may increase the anticoagulant activities of Phenprocoumon.Investigational
PyrimethamineThe metabolism of Phenprocoumon can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Phenprocoumon.Approved
QuingestanolQuingestanol may decrease the anticoagulant activities of Phenprocoumon.Experimental
QuinidineQuinidine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
QuinineQuinine may increase the anticoagulant activities of Phenprocoumon.Approved
RabeprazoleThe metabolism of Phenprocoumon can be decreased when combined with Rabeprazole.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Phenprocoumon.Investigational
RanolazineThe metabolism of Phenprocoumon can be decreased when combined with Ranolazine.Approved, Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Phenprocoumon.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Phenprocoumon.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ReviparinPhenprocoumon may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Phenprocoumon.Approved
RifabutinThe metabolism of Phenprocoumon can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Phenprocoumon can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Phenprocoumon can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Phenprocoumon can be increased when combined with Rifaximin.Approved, Investigational
RivaroxabanPhenprocoumon may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
RonifibrateRonifibrate may increase the anticoagulant activities of Phenprocoumon.Experimental
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
RosoxacinRosoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
RucaparibThe metabolism of Phenprocoumon can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinRufloxacin may increase the anticoagulant activities of Phenprocoumon.Experimental
SalicylamideSalicylamide may increase the anticoagulant activities of Phenprocoumon.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Phenprocoumon.Approved
SaquinavirThe metabolism of Phenprocoumon can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Phenprocoumon.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Phenprocoumon.Experimental
SecobarbitalThe metabolism of Phenprocoumon can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Phenprocoumon.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Phenprocoumon.Approved
SeliciclibSeliciclib may increase the anticoagulant activities of Phenprocoumon.Investigational
SemapimodSemapimod may increase the anticoagulant activities of Phenprocoumon.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Phenprocoumon.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Phenprocoumon.Investigational
SertralineSertraline may increase the anticoagulant activities of Phenprocoumon.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
SildenafilThe metabolism of Phenprocoumon can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Phenprocoumon can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Phenprocoumon can be increased when it is combined with Simeprevir.Approved
SimfibrateSimfibrate may increase the anticoagulant activities of Phenprocoumon.Experimental
SitafloxacinSitafloxacin may increase the anticoagulant activities of Phenprocoumon.Experimental, Investigational
Sodium CitratePhenprocoumon may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SolithromycinThe serum concentration of Phenprocoumon can be increased when it is combined with Solithromycin.Investigational
SorafenibThe metabolism of Phenprocoumon can be decreased when combined with Sorafenib.Approved, Investigational
SparfloxacinSparfloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Phenprocoumon.Investigational
St. John's WortThe metabolism of Phenprocoumon can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the anticoagulant activities of Phenprocoumon.Illicit, Investigational
StanozololStanozolol may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
StiripentolThe serum concentration of Phenprocoumon can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of hemorrhage can be increased when Streptokinase is combined with Phenprocoumon.Approved, Investigational
SucralfateSucralfate may decrease the anticoagulant activities of Phenprocoumon.Approved
SugammadexSugammadex may increase the anticoagulant activities of Phenprocoumon.Approved
SulbenicillinSulbenicillin may increase the anticoagulant activities of Phenprocoumon.Experimental
SulfadiazineThe metabolism of Phenprocoumon can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the anticoagulant activities of Phenprocoumon.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Phenprocoumon.Approved
SulfinpyrazoneThe metabolism of Phenprocoumon can be decreased when combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Phenprocoumon can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
SulodexidePhenprocoumon may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SultamicillinSultamicillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Phenprocoumon.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Phenprocoumon.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Phenprocoumon.Approved
TalampicillinTalampicillin may increase the anticoagulant activities of Phenprocoumon.Experimental
TalniflumateTalniflumate may increase the anticoagulant activities of Phenprocoumon.Approved
TamoxifenTamoxifen may increase the anticoagulant activities of Phenprocoumon.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Phenprocoumon.Investigational
TegafurThe serum concentration of Phenprocoumon can be increased when it is combined with Tegafur.Approved, Investigational
TelaprevirThe metabolism of Phenprocoumon can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Phenprocoumon can be decreased when combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the anticoagulant activities of Phenprocoumon.Withdrawn
TenecteplaseTenecteplase may increase the anticoagulant activities of Phenprocoumon.Approved
TenidapTenidap may increase the anticoagulant activities of Phenprocoumon.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Phenprocoumon.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Phenprocoumon.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Phenprocoumon.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Phenprocoumon.Investigational
TestosteroneTestosterone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Testosterone cypionateThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Testosterone enanthate.Approved
Testosterone propionateTestosterone propionate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
TetracyclineTetracycline may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
ThiamylalThe metabolism of Phenprocoumon can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Phenprocoumon can be increased when combined with Thiopental.Approved, Vet Approved
Thyroid, porcineThyroid, porcine may increase the anticoagulant activities of Phenprocoumon.Approved
TianeptineTianeptine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Phenprocoumon.Approved
TiboloneTibolone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TicagrelorThe metabolism of Phenprocoumon can be decreased when combined with Ticagrelor.Approved
TicarcillinTicarcillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Vet Approved
TiclopidineThe metabolism of Phenprocoumon can be decreased when combined with Ticlopidine.Approved
TinoridineTinoridine may increase the anticoagulant activities of Phenprocoumon.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Phenprocoumon.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Phenprocoumon.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Phenprocoumon.Approved
TocilizumabThe serum concentration of Phenprocoumon can be decreased when it is combined with Tocilizumab.Approved
TolazamideTolazamide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TolbutamideThe metabolism of Phenprocoumon can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Phenprocoumon.Approved
TopiroxostatThe metabolism of Phenprocoumon can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneToremifene may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Tositumomab.Approved, Investigational
TramadolTramadol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Phenprocoumon.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TriamcinoloneTriamcinolone may increase the anticoagulant activities of Phenprocoumon.Approved, Vet Approved
TribenosideTribenoside may increase the anticoagulant activities of Phenprocoumon.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
TrimethoprimThe metabolism of Phenprocoumon can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the anticoagulant activities of Phenprocoumon.Approved
TriptolideTriptolide may increase the anticoagulant activities of Phenprocoumon.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Phenprocoumon.Approved
TrovafloxacinTrovafloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
TroxerutinPhenprocoumon may increase the anticoagulant activities of Troxerutin.Investigational
TylosinThe serum concentration of Phenprocoumon can be increased when it is combined with Tylosin.Vet Approved
UlipristalUlipristal may decrease the anticoagulant activities of Phenprocoumon.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Phenprocoumon can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Phenprocoumon can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Phenprocoumon can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenprocoumon.Approved
VerapamilThe metabolism of Phenprocoumon can be decreased when combined with Verapamil.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Phenprocoumon.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Phenprocoumon.Approved
VoriconazoleThe serum concentration of Phenprocoumon can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
WarfarinWarfarin may increase the anticoagulant activities of Phenprocoumon.Approved
XimelagatranPhenprocoumon may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe serum concentration of Phenprocoumon can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Phenprocoumon.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the anticoagulant activities of Phenprocoumon.Withdrawn
ZiprasidoneThe metabolism of Phenprocoumon can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Phenprocoumon.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015081
PubChem Compound
54680692
PubChem Substance
46506423
ChemSpider
10441592
BindingDB
768
ChEBI
50438
ChEMBL
CHEMBL1465
Therapeutic Targets Database
DAP000771
PharmGKB
PA450921
Wikipedia
Phenprocoumon
ATC Codes
B01AA04 — Phenprocoumon

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableMalignant Melanoma, Neoplasms1
2TerminatedTreatmentHaemorrhage / Thrombosis1
3Not Yet RecruitingTreatmentEnd-Stage Kidney Disease / Nonvalvular Atrial Fibrillation1
3RecruitingTreatmentNonvalvular Atrial Fibrillation1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism (VTE)1
3Unknown StatusNot AvailableDeep Venous Thrombosis1
4Active Not RecruitingBasic ScienceAtrial Fibrillation or Pulmonary Embolism / Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location / Need of Long Term Oral Anticoagulation Therapy (OAT)1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
4CompletedTreatmentHip Replacement Postoperative / Knee Replacement Postoperative / Nonvalvular Atrial Fibrillation / Pulmonary Embolism (PE)1
4CompletedTreatmentNonvalvular Atrial Fibrillation2
4RecruitingPreventionNonvalvular Atrial Fibrillation1
4RecruitingTreatment(Atrial Fibrillation) or (Atrial Flutter) / Thrombosis of Left Atrial Appendage1
4RecruitingTreatmentCervical Artery Dissection1
4RecruitingTreatmentLeft Atrial Thrombosis / Nonvalvular Atrial Fibrillation1
4TerminatedTreatmentAcute Coronary Syndromes (ACS) / Atherosclerosis / Coronary Heart Disease (CHD) / Nonvalvular Atrial Fibrillation1
4TerminatedTreatmentMechanical Heart Valve Recipients1
4WithdrawnTreatmentCoronary Heart Disease (CHD) / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Elevation Myocardial Infarction (STEMI) / Stable Angina (SA) / Unstable Angina (UA)1
Not AvailableActive Not RecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation3
Not AvailableCompletedNot AvailableUnsuspected Pulmonary Embolism1

Pharmacoeconomics

Manufacturers
  • Organon usa inc
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)179.5 °CPhysProp
water solubility12.9 mg/LNot Available
logP3.62HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0486 mg/mLALOGPS
logP3.81ALOGPS
logP3.74ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)6.44ChemAxon
pKa (Strongest Basic)-6.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity81.64 m3·mol-1ChemAxon
Polarizability29.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.8992
Caco-2 permeable+0.8924
P-glycoprotein substrateSubstrate0.5545
P-glycoprotein inhibitor INon-inhibitor0.8579
P-glycoprotein inhibitor IINon-inhibitor0.8896
Renal organic cation transporterNon-inhibitor0.8798
CYP450 2C9 substrateNon-substrate0.6832
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.687
CYP450 1A2 substrateInhibitor0.6462
CYP450 2C9 inhibitorInhibitor0.7572
CYP450 2D6 inhibitorNon-inhibitor0.9555
CYP450 2C19 inhibitorNon-inhibitor0.5
CYP450 3A4 inhibitorNon-inhibitor0.9032
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6013
Ames testNon AMES toxic0.8363
CarcinogenicityNon-carcinogens0.9044
BiodegradationNot ready biodegradable0.8477
Rat acute toxicity3.1784 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9105
hERG inhibition (predictor II)Non-inhibitor0.9479
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.9 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Hydroxycoumarins
Direct Parent
4-hydroxycoumarins
Alternative Parents
1-benzopyrans / Phenylpropanes / Pyranones and derivatives / Vinylogous acids / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
4-hydroxycoumarin / Benzopyran / 1-benzopyran / Phenylpropane / Pyranone / Monocyclic benzene moiety / Benzenoid / Pyran / Heteroaromatic compound / Vinylogous acid
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
hydroxycoumarin (CHEBI:50438)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vitamin-k-epoxide reductase (warfarin-sensitive) activity
Specific Function
Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the...
Gene Name
VKORC1
Uniprot ID
Q9BQB6
Uniprot Name
Vitamin K epoxide reductase complex subunit 1
Molecular Weight
18234.3 Da
References
  1. Schalekamp T, Brasse BP, Roijers JF, van Meegen E, van der Meer FJ, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007 Feb;81(2):185-93. Epub 2006 Dec 27. [PubMed:17192772]
  2. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR: A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005 Oct;2(10):e312. Epub 2005 Oct 11. [PubMed:16201835]
  3. Thijssen HH, Baars LG: Microsomal warfarin binding and vitamin K 2,3-epoxide reductase. Biochem Pharmacol. 1989 Apr 1;38(7):1115-20. [PubMed:2706010]
  4. Thijssen HH, Baars LG, Vervoort-Peters HT: Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity. Br J Pharmacol. 1988 Nov;95(3):675-82. [PubMed:3207986]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Schalekamp T, Brasse BP, Roijers JF, van Meegen E, van der Meer FJ, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007 Feb;81(2):185-93. Epub 2006 Dec 27. [PubMed:17192772]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Niedner R, von Oettingen U, Meyer F: [The reciprocal actions of phenprocoumon (Marcumar) with human serum albumin, erythrocytes and blood]. Int J Clin Pharmacol Biopharm. 1975 Dec;12(4):446-57. [PubMed:1205658]
  2. Fitos I, Visy J, Simonyi M: Species-dependency in chiral-drug recognition of serum albumin studied by chromatographic methods. J Biochem Biophys Methods. 2002 Dec 31;54(1-3):71-84. [PubMed:12543492]
  3. Fitos I, Simonyi M: Stereoselective effect of phenprocoumon enantiomers on the binding of benzodiazepines to human serum albumin. Chirality. 1992;4(1):21-3. [PubMed:1642965]
  4. Rehse K, Fiedler B: [Determination of the protein binding of drugs by continuous ultrafiltration. 9. Comparison of the binding of nonsteroid antirheumatics to human serum albumin and their interaction with phenprocoumon]. Arch Pharm (Weinheim). 1989 Apr;322(4):241-3. [PubMed:2751413]
  5. Niedner R, von Oettingen U, Meyer F: [Binding of phenprocoumarol (Marcumar) to human albumin]. Int J Clin Pharmacol. 1973 Oct;8(2):160-6. [PubMed:4762907]
Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Otagiri M, Maruyama T, Imai T, Imamura Y: Fluorescent investigations of binding of phenprocoumon to alpha 1-acid glycoprotein. J Pharm Sci. 1987 Aug;76(8):646-9. [PubMed:11002825]
  2. Hazai E, Visy J, Fitos I, Bikadi Z, Simonyi M: Selective binding of coumarin enantiomers to human alpha1-acid glycoprotein genetic variants. Bioorg Med Chem. 2006 Mar 15;14(6):1959-65. Epub 2005 Nov 15. [PubMed:16290938]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:27